The leading brain imaging analysis software. One powerful diagnostic tool available for multiple modalities and clinical applications.

A clear picture of dementia. A major impact on therapy.

NeuroQ

TM

The Integrated Solution for FDG, Amyloid, SPECT, DaTscan and Epilepsy.

Advanced Tools. Advanced Workflow.

SOLUTIONS

Fully Integrated Multi-Modality

Learn More

Non-invasive analysis to determine the likelihood that TLE patients will be seizure-free post surgery. 

Epilepsy

Learn More

An effective way to monitor disease progression

Serial Compare

Learn More

Integrated analysis to assist 
with quantified comparisons of Ioflupane I-123 studies

DaTscan

Learn More

Integrated analysis specifically designed for Amyloid scans

Amyloid Analysis

Learn More

NeuroQ™, a streamlined, single platform supports the most relevant functional imaging modalities, increasing accuracy in differential diagnosis.

TM

SPECT

Learn More

NeuroQ™ is one of the most widely used quantitative tools for differential diagnosis of dementia.

PET-FDG

The easiest HIPPA compliant cloud reading & reporting solution

Syntermed Live

Remote Reading

TM

Learn More

More than 30% of patients with dementia are misdiagnosed. Using FDG-PET in the diagnosis of dementia increases the accuracy of the diagnosis to approximately 90%.

NeuroQ goes beyond the visual read and provides valuable non-subjective diagnostic information. Metabolic levels in more than 240 pre-defined regions of the brain are rapidly compared to those in the normal database and quantified to show the degree of abnormality and statistical significance of the findings.

Daniel Silverman, M.D. PhD, head of Neuronuclear Imaging section, David Geffen School of Medicine at UCLA said "For patients whose clinical work-up has not led to a definitive diagnosis, brain PET is currently our single best tool to differentiate dementias, especially in the early stages of the disease. Adding quantitative analysis to PET can further improve the ability to diagnose the cause of the dementia."


Dan Silverman, M.D., PhD.

Distinguishing Between Dementias

What is NeuroQ? An introduction from its developer, Daniel Silverman, MD, PhD, head of Neuronuclear Imaging section, David Geffen School of Medicine at UCLA.

Terms of use & privacy policy

©2022 SYNTERMED INC. - ALL RIGHTS RESERVED. | FOR PERMISSION, EMAIL 

Emory Toolbox is a trademark of Emory University.    AdreView, Xeleris, DaTscan, Vizamyl and GE are trademarks of General Electric Company.
Amyvid is a trademark of Eli Lilly and Company.    NeuraCeq is a trademark of Piramal Imaging.    ImageGuide is a trademark of the American Society of Nuclear Cardiology.   
PYLARIFY AI is a Trademark of Lantheus Holdings, Inc.

Syntermed medical devices have received FDA (Quality System Records/Pre-Market Notfication) 510(k) clearance and European Union (ISO 13485:2016 FM 670241/CE Mark 696491) regulations. See eIFU for ECTb and NeuroQ.

Syntermed, Inc.
333 Sandy Springs Circle NE, Suite 107, Atlanta, GA 30328

TEL (888) 263-4446 | FAX (888) 216-7511

Privacy Notice    

HIPAA     

MSA